常染色体显性多囊肾病的代谢重编程:证据与治疗潜力
常染色体显性多囊肾病以肾脏囊肿进行性发展并导致终末期肾病为特征性表现。体外与动物模型证据提示该病存在代谢缺陷,包括葡萄糖代谢重编程、脂质与氨基酸代谢异常、自噬受损及线粒体功能障碍,可能促进囊肿上皮增殖与囊肿生长。针对代谢异常的饮食与药物策略正在被考虑用于延缓疾病进展,但人体证据有限,初始临床试验结果尚待公布。
要点
- ADPKD 体外与动物模型存在代谢缺陷,可能促进囊肿生长。
- 人体肾脏代谢失调证据有限,需更多机制研究。
- 靶向代谢的饮食与药物策略正被评估用于延缓 ADPKD 进展。
核心结论
- ADPKD 体外与动物模型存在代谢缺陷,可能促进囊肿上皮增殖与囊肿生长。
- 有限证据支持 ADPKD 患者肾脏细胞代谢亦失调。
- 靶向代谢异常的饮食与药物策略有望延缓 ADPKD 进展,但初始临床试验结果尚待公布。
研究设计与样本
- 综述性文章,汇总体外与动物模型及有限人体证据,讨论代谢重编程在 ADPKD 中的作用与治疗潜力。
主要发现
- ADPKD 模型存在葡萄糖代谢重编程(倾向有氧糖酵解)、脂质与氨基酸代谢失调、自噬受损及线粒体功能障碍。
- 有限证据支持 ADPKD 患者肾脏细胞代谢亦失调。
- 代谢、肥胖和/或 ADPKD 之间存在显著重叠特征与通路。
关键数值与推荐
- 饮食策略包括每日热量限制、间歇性禁食、限时进食、生酮饮食、2-脱氧葡萄糖及改变营养素可利用性。
- 药物策略包括 AMP 活化激酶激活剂、钠-葡萄糖共转运蛋白-2 抑制剂、烟酰胺及噻唑烷二酮类。
- 可考虑将代谢靶向治疗与针对其他信号通路的药物(如托伐普坦)联合。
临床怎么用
- 临床可关注 ADPKD 患者代谢异常,但靶向代谢治疗尚需临床试验验证。
- 饮食与药物代谢策略可作为未来延缓 ADPKD 进展的潜在方向。
局限性
- 人体证据有限,多数机制证据来自体外与动物模型。
- 靶向代谢的初始临床试验结果尚未公布。
- 需更多机制研究以理解代谢失调在 ADPKD 中的作用并转化为临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of kidney cysts, leading to ESKD. Because the kidneys are under high metabolic demand, it is not surprising that mounting evidence suggests that a metabolic defect exists in in vitro and animal models of autosomal dominant polycystic kidney disease, which likely contributes to cystic epithelial proliferation and subsequent cyst growth. Alterations include defective glucose metabolism (reprogramming to favor aerobic glycolysis), dysregulated lipid and amino acid metabolism, impaired autophagy, and mitochondrial dysfunction. Limited evidence supports that cellular kidney metabolism is also dysregulated in humans with autosomal dominant polycystic kidney disease. There are notable overlapping features and pathways among metabolism, obesity, and/or autosomal dominant polycystic kidney disease. Both dietary and pharmacologic-based strategies targeting metabolic abnormalities are being considered as therapies to slow autosomal dominant polycystic kidney disease progression and are attractive, particularly given the slowly progressive nature of the disease. Dietary strategies include daily caloric restriction, intermittent fasting, time-restricted feeding, a ketogenic diet, and 2-deoxy-glucose as well as alterations to nutrient availability. Pharmacologic-based strategies include AMP-activated kinase activators, sodium glucose cotransporter-2 inhibitors, niacinamide, and thiazolidenediones. The results from initial clinical trials targeting metabolism are upcoming and anxiously awaited within the scientific and polycystic kidney disease communities. There continues to be a need for additional mechanistic studies to better understand the role of dysregulated metabolism in autosomal dominant polycystic kidney disease and for subsequent translation to clinical trials. Beyond single-intervention trials focused on metabolic reprograming in autosomal dominant polycystic kidney disease, great potential also exists by combining metabolic-focused therapeutic approaches with compounds targeting other signaling cascades altered in autosomal dominant polycystic kidney disease, such as tolvaptan.
引用
- Nowak KL, Hopp K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin J Am Soc Nephrol. 2020. PMID: 32086281. doi:10.2215/CJN.13291019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。